Docetaxel Versus Surveillance After Radical Radiotherapy for Intermediate- or High-risk Prostate Cancer—Results from the Prospective, Randomised, Open-label Phase III SPCG-13 Trial-Reference-Cited by-同舟云学术

Docetaxel Versus Surveillance After Radical Radiotherapy for Intermediate- or High-risk Prostate Cancer—Results from the Prospective, Randomised, Open-label Phase III SPCG-13 Trial

Published:2019-12 Issue:6 Volume:76 Page:823-830
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Kellokumpu-Lehtinen Pirkko-Liisa^ORCID,Hjälm-Eriksson Marie,Thellenberg-Karlsson Camilla,Åström Lennart,Franzen Lars,Fransson Ann-Sofie,Leskinen Markku J.,Zeke Mihalj,Huttunen Teppo,Ginman Claes

Publisher

Elsevier BV

Subject

Urology

Reference28 articles.

1. Clinically localized prostate cancer: AUA/ASTRO/SUO guideline. Part I: risk stratification, shared decision making, and care options;Sandra;J Urol,2018

2. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis and local treatment with curative intent;Mottet;Eur Urol,2017

3. Natural history of surgically treated high-risk prostate cancer;Briganti;Urol Oncol,2015

4. National Comprehensive Cancer Network. National comprehensive Cancer network guidelines. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf.

5. Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer consensus Conference APCCC 2017;Gillessen;Eur Urol,2018

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hormonal Agents in Localized and Advanced Prostate Cancer: Current Use and Future Perspectives;Clinical Genitourinary Cancer;2024-10

2. Secondary analysis of late major gastrointestinal and genitourinary toxicities in unfavorable‐risk prostate cancer patients receiving docetaxel: Insights from a randomized trial;Cancer;2024-03

3. Approach to Patients with High-Risk Localized Prostate Cancer: Radiation Oncology Perspective;Current Treatment Options in Oncology;2024-01

4. Novel Approaches in the Systemic Management of High-Risk Prostate Cancer;Clinical Genitourinary Cancer;2023-12

5. Mortality Risk for Docetaxel-Treated, High-Grade Prostate Cancer With Low PSA Levels;JAMA Network Open;2023-11-01